Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
19.33
-1.07 (-5.25%)
Nov 5, 2026, 4:00 PM EST - Market closed
Anika Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 259 | 139 | 241 | 332 | 432 | 517 | |
Market Cap Growth | 82.69% | -42.51% | -27.34% | -23.28% | -16.40% | -19.60% |
Enterprise Value | 246 | 105 | 206 | 290 | 376 | 447 |
Last Close Price | 19.33 | 9.61 | 16.46 | 22.66 | 29.60 | 35.83 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 125.13 |
Forward PE | 21.72 | 53.39 | 39.19 | 72.08 | 72.08 | 112.55 |
PS Ratio | 2.14 | 1.23 | 2.01 | 2.75 | 3.80 | 3.50 |
PB Ratio | 1.88 | 0.97 | 1.57 | 1.56 | 1.51 | 1.80 |
P/TBV Ratio | 2.02 | 1.04 | 1.67 | 1.64 | 2.12 | 2.63 |
P/FCF Ratio | 460.31 | 31.77 | - | - | - | 158.96 |
P/OCF Ratio | 43.28 | 12.39 | 44.62 | - | 98.08 | 61.60 |
PEG Ratio | 2.17 | 11.40 | 1.96 | 3.60 | 3.60 | 161.40 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.04 | 0.93 | 1.72 | 2.40 | 3.30 | 3.03 |
EV/EBITDA Ratio | 80.77 | - | 172.87 | 45.74 | 41.04 | 194.39 |
EV/EBIT Ratio | - | - | - | 344.10 | 102.39 | - |
EV/FCF Ratio | 436.89 | 24.10 | - | - | - | 137.51 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.18 | 0.18 | 0.17 | 0.13 | 0.11 | 0.07 |
Debt / EBITDA Ratio | 8.31 | - | 5.25 | 2.75 | 2.49 | 4.12 |
Debt / FCF Ratio | 44.93 | 6.02 | - | - | - | 6.44 |
Net Debt / Equity Ratio | -0.10 | -0.22 | -0.19 | -0.19 | -0.19 | -0.26 |
Net Debt / EBITDA Ratio | -4.33 | 5.71 | -24.89 | -6.46 | -6.05 | -31.90 |
Net Debt / FCF Ratio | -23.42 | -7.16 | 12.74 | 5.68 | 18.02 | -22.57 |
Asset Turnover | 0.65 | 0.57 | 0.51 | 0.39 | 0.33 | 0.41 |
Inventory Turnover | 2.01 | 2.30 | 1.80 | 1.19 | 1.07 | 1.42 |
Quick Ratio | 3.05 | 3.71 | 3.40 | 3.06 | 4.33 | 4.17 |
Current Ratio | 4.48 | 4.72 | 4.88 | 5.26 | 6.07 | 5.66 |
Return on Equity (ROE) | -2.19% | -6.71% | -4.82% | -1.38% | 0.77% | 1.48% |
Return on Assets (ROA) | -0.87% | -3.52% | -1.19% | 0.17% | 0.66% | -2.11% |
Return on Invested Capital (ROIC) | -2.14% | -9.35% | -3.04% | -0.46% | 0.84% | -5.86% |
Return on Capital Employed (ROCE) | -1.60% | -6.60% | -2.50% | 0.40% | 1.10% | -3.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -1.43% | -7.85% | -23.39% | -24.92% | -3.44% | 0.80% |
FCF Yield | 0.22% | 3.15% | -0.97% | -2.17% | -0.71% | 0.63% |
Buyback Yield / Dilution | 4.23% | 2.60% | -0.44% | -0.65% | 0.50% | -2.90% |